Department of Neurology, Fixel Institute for Neurological Diseases, University of Florida, Gainesville, FL, USA.
Curr Neurol Neurosci Rep. 2022 Feb;22(2):123-142. doi: 10.1007/s11910-022-01177-8. Epub 2022 Feb 2.
This study aims to examine the treatments currently available for Tourette syndrome (TS) and to discuss evolving therapies, spanning behavioral, pharmacologic, complementary and alternative medicine, and neuromodulation approaches.
Behavioral therapies have undergone several modifications to improve accessibility, including transitioning to a virtual format which is particularly important in the current pandemic. There are several recent or ongoing pharmacologic studies that have shown promise including the selective D1 receptor antagonist ecopipam and various cannabinoid compounds. Adaptive DBS may enable the physiologic markers of tics to determine stimulation parameters and improve tic outcomes related to neuromodulation. In recent years, there has been a wealth of research across multiple treatment domains in the TS field. This review highlights exciting and new potential options for the future treatment of patients with TS.
本研究旨在探讨目前可用于妥瑞氏综合征（TS）的治疗方法，并讨论不断发展的治疗方法，包括行为、药物、补充和替代医学以及神经调节方法。
行为疗法已经进行了几次修改，以提高可及性，包括过渡到虚拟格式，这在当前大流行期间尤为重要。有几项最近或正在进行的药物研究显示出希望，包括选择性 D1 受体拮抗剂 ecopipam 和各种大麻素化合物。适应性 DBS 可以使 tic 的生理标志物来确定刺激参数，并改善与神经调节相关的 tic 结果。近年来，TS 领域在多个治疗领域都有大量的研究。本综述强调了未来治疗 TS 患者的令人兴奋和新的潜在选择。
